Publications

Antimicrobial activity of dalbavancin and comparators against Staphylococcus aureus causing pneumonia in patients with and without cystic fibrosis. by Sader HS, Duncan LR and Mendes RE. published in Int. J. Infect. Dis. 2021; 107: 69-71

Susceptibility trends of ceftolozane/tazobactam and comparators when tested against U. S. gram-negative bacterial surveillance isolates (2012-2018). by Shortridge D, Carvalhaes CG, Streit JM and Flamm RK. published in Diag. Microbio. Infect. Dis. 2021; 100 (1): 11530

Antimicrobial activity of dalbavancin against clinical isolates of coagulase-negative staphylococci from the USA and Europe stratified by species. by Sader HS, Carvalhaes CG, Streit JM, Arends SJR and Mendes RE. published in J Glob Antimicrob Resist. 2021; 24: 48-52

Evaluation of synergistic activity of isavuconazole or voriconazole plus anidulafungin and the occurrence and genetic characterisation of Candida auris detected in a surveillance program. by Pfaller MA, Messer SA, Deshpande LM, Rhomberg PR, Utt EA and Castanheira M published in Antimicrob. Agents Chemother.: 2021; 65 (4): e02031

Ceftaroline activity against Staphylococcus aureus isolated from patients with infective endocarditis, worldwide (2010-2019). by Sader HS, Carvalhaes CG and Mendes RE. published in Int. J. Infect. Dis. 2021; 102: 524-528

In vitro activity and potency of the novel oxazolidinone contezolid (MRX-I) tested against Gram-positive clinical isolates from the United States and Europe. by Carvalhaes CG, Duncan LR, Wang W and Sader HS. published in Antimicrob. Agents Chemother. 2020; 64 (11): e01195

Comparison of minimum inhibitory concentration results for gepotidacin obtained using agar dilution and broth microdilution methods. by Arends SJR, Canino MA, Mendes R, Scangarella-Oman NE and Flamm RK. published in >Diagn. Microbiol. Infect. Dis. 2020; 98 (2): 115107

Activity of Novel β-lactamase Inhibitor QPX7728 Combined with β-lactams Against ST258 Klebsiella pneumoniae and ST131 Escherichia coli isolates Producing β-lactamases. Lead author Mariana Castanheira. Presented at IDWeek 2020.

Presentation #166

Activity of cefiderocol alone and in combination with levofloxacin, minocycline, polymyxin B, or trimethoprim-sulfamethoxazole against multidrug-resistant Stenotrophomonas maltophilia. by Biagi M, Vialichka A, Jurkovic M, Wu T, Shajee A, Lee M, Patel S, Mendes RE and Wenzler E published in Antimicrob. Agents Chemother. 2020; 64 (9): e00559

Frequency and antimicrobial susceptibility of bacteria causing bloodstream infections in pediatric patients from United States (US) medical centers (2014-2018): Therapeutic options for multidrug-resistant bacteria. by Sader HS, Castanheira M, Streit JM, Carvalhaes CG and Mendes RE published in Diagn. Microbiol. Infect. Dis. 2020; 98 (2): 115108

In vitro activity analysis of a new generation polymyxin, SPR741, tested in combination with antimicrobial agents against a challenge set of Enterobacteriaceae, including molecularly characterized strains. by Mendes RE, Rhomberg PR, Lister T, Cotroneo N, Parr TR and Castanheira M. published in Antimicrob. Agents Chemother.: in press, 2020.

Ceftaroline Activity against Staphylococcus aureus Isolated from Patients with Infective Endocarditis Worldwide (2010-2019). Lead author: HS Sader, presented at CHEST 2020, October 18-21, Virtual Conference
Poster #P0447

Antimicrobial Activity of Dalbavancin and Comparators against Staphylococcus aureus causing Pneumonia in Patients with and without Cystic Fibrosis. Lead author: HS Sader, presented at NACFC 2020, October 21-23, Virtual Conference
Poster #347

Antimicrobial Activity of Ceftazidime-Avibactam and Comparator Agents against Pseudomonas aeruginosa and Enterobacterales Causing Pneumonia in Cystic Fibrosis Patients. Lead author: HS Sader, presented at NACFC 2020, October 21-23, Virtual Conference
Poster #315

Update on the activity of delafloxacin on acute bacterial skin and skin structure infection isolates from European hospitals (2014-2019). by Shortridge D, Pfaller MA, Streit JM and Flamm RK. published in J. Glob. Antimicrob. Resist. 2020; 23: 278

Analysis of a Worldwide Collection of Klebsiella pneumoniae CC258 with Reference to Carbapenemase Production Using the 1928 Core Genome (cg) Multilocus Sequence Type (MLST) Reveals Endemicity and the Global Dissemination of Clones. Lead author Lalitagauri Deshpande. Presented at IDWeek 2020.

Poster #831

Minocycline Activity Against Unusual Clinically Significant Gram-Negative Pathogens. Lead author: Dee Shortridge. Presented at IDWeek 2020.

Poster #1620

Activity of Meropenem-Vaborbactam and Comparators Against Globally Disseminated Klebsiella pneumoniae Sequence Type 258. Lead Author: Lalitagauri Deshpande. Presented at IDWeek2020.

Poster #1589

Media for colistin susceptibility testing does not improve the detection of Klebsiella pneumoniae isolates carrying MgrB disruption and other mutation driven colistin resistance mechanisms. by Castanheira M, Doyle TB, Carvalhaes CG, Roth BM, Rhomberg PR and Mendes RE. published in Diagn. Microbiol. Infect. Dis. 2020; 98 (1): 115077

Activity of Posaconazole and Comparator Antifungal Agents Tested Against Filamentous Fungi. Lead Author: Mariana Castanheira. Presented at IDWeek 2020.

Poster #1148

Impact of Different Breakpoint Criteria on the Susceptibility Rates of Enterobacterales-Resistant Subsets to the Aminoglycosides. Primary Author: Helio Sader. Presented at IDWeek 2020.

Poster #1278

Antimicrobial Activity of Dalbavancin against Clinical Isolates of Coagulase-Negative Staphylococci (CoNS) from United States and Europe Stratified by Species. Lead Author: Helio Sader. Presented at IDWeek 2020.

Poster #1449

Bloodstream Infections in the United States and Europe: Etiology and Antimicrobial Susceptibility Results from the SENTRY Antimicrobial Surveillance Program (2016-2019). Lead Author: Helio Sader. Presented at IDWeek 2020. 

Presentation #37

Plazomicin Activity against Enterobacterales Isolates Producing Extended-Spectrum β-Lactamases (ESBLs), Carbapenemases, and Aminoglycoside-Modifying Enzymes (AMEs) from United States (US) Hospitals. Lead Author: Mariana Castanheira. Presented at IDWeek 2020.

Poster #1278

Antimicrobial Activity of Gepotidacin against Clinical Isolates of Escherichia coli and Staphylococcus saprophyticus Collected Worldwide in 2019. Lead Author: SJ Ryan Arends. Presented at IDWEEK 2020.

Poster #1262

Update on Prevalence of mcr-like Genes Among Enterobacterales in a Global Surveillance Program: Decline in Occurrence of mcr-1.1 and Emergence of mcr-9.1 and mcr-10.1. Lead Author: Lalitagauri Deshpande. Presented at IDWeek 2020.

Presentation Number: 166.

Activity of Posaconazole versus Voriconazole for the Treatment of Invasive Aspergillosis in Adults Enrolled in a Clinical Trial. Lead Author: Mariana Castanheira. Presented at IDWeek 2020.

Poster #1169

In Vitro Selection of Enterobacter cloacae with Cefepime, Meropenem, and Ceftazidime-avibactam Generate Diverse Resistance Mechanisms. Lead Author: Mariana Castanheira. Presented at IDWeek 2020.

Presentation #26

Ceftobiprole Activity against Gram-Positive Pathogens Causing Bone and Joint Infections in the United States from 2016 through 2019. Lead author: LR Duncan, presented at IDWeek 2020, October 21-22, Virtual Conference
Poster #1595

Activity of Meropenem-Vaborbactam and Comparators Against Globally Disseminated Klebsiella pneumoniae Sequence Type 258. Lead author: D Shortridge presented at IDWeek 2020, October 21-22, Virtual Conference
Poster #1589

Oritavancin Activity against Staphylococcus aureus Isolates Causing Bone and Joint Infection in European Hospitals (2010-2019). Lead author: CG Carvalhaes presented at IDWeek 2020, October 21-22, Virtual Conference
Poster #327

Activity of Tedizolid and Comparator Agents against Gram-Positive Bacterial Isolates Causing Skin and Skin Structure Infections in Pediatric Patients during 2015-2019 in the US. Lead author: CG Carvalhaes presented at IDWeek 2020, October 21-22, Virtual Conference
Poster # 1547

Activity of Delafloxacin against Multi-Drug-Resistant Fastidious Respiratory Pathogens from European Medical Centers (2014-2019). Lead author: D Shortridge presented at IDWeek 2020, October 21-22, Virtual Conference
Poster #1463

Tedizolid Activity against Gram-Positive Bacterial Isolates Causing Bone and Joint Infections in the United States (2015-2019). Lead author: CG Carvalhaes presented at IDWeek 2020, October 21-22, Virtual Conference
Poster #333

Antimicrobial Activity of Aztreonam-Avibactam against Gram-Negative Bacteria Isolated from Patients Hospitalized with Pneumonia in Europe, Latin America, and Asia in 2019. Lead author: HS Sader, presented at IDWeek 2020, October 21-22, Virtual Conference
Poster #1261

In Vitro Activity of Omadacycline against 7,000 Bacterial Pathogens from the United States Stratified by Infection Type (2019). Lead author: MD Huband, presented at IDWeek 2020, October 21-22, Virtual Conference
Poster #1253

Analysis of a Worldwide Collection of Klebsiella pneumoniae CC258 with Reference to Carbapenemase Production Using the 1928 Core Genome (cg) Multilocus Sequence Type (MLST) Reveals Endemicity and the Global Dissemination of Clones. Lead author: LM Deshpande presented at IDWeek2020, October 21-22, Virtual Conference
Poster #831

Minocycline Activity Against Unusual Clinically Significant Gram-Negative Pathogens. Lead author: D Shortridge presented at IDWeek 2020, October 21-22, Virtual Conference
Poster #1620

Activity of meropenem-vaborbactam and single-agent comparators against Enterobacterales isolates, including KPC-producing isolates, from European patients hospitalized with pneumonia including ventilator-associated pneumonia (2014-2019). Lead author: D Shortridge presented at IDWeek 2020, October 21-22, Virtual Conference
Poster #1590

Activity of Ceftazidime-Avibactam against Carbapenemase-negative Carbapenem-resistant Enterobacterales (CRE) isolates from US Hospitals. Lead author: M Castanheira presented at IDWeek 2020, October 21-22, Virtual Conference
Poster #1443

Frequency of Occurrence and Antimicrobial Susceptibility of Bacteria Isolated from Patients Hospitalized with Bacterial Pneumonia in the United States, Western Europe, and Eastern Europe: Results from the SENTRY Program (2016-2019). Lead author: H Sader, presented at IDWeek 2020, October 21-22, Virtual Conference
Poster #2020

Comparative Epidemiological Analysis of Serratia marcescens using PFGE and Whole Genome Sequence Methods. Lead author: LM Deshpande presented at ID Week 2020, October 21-22, Virtual Conference
Poster #826

Activity of a Series of Investigational Compounds Tested Against Invasive Fungal Isolates. Lead author: PR Rhomberg, presented at IDWeek 2020, October 21-22, Virtual Conference
Poster #1258

Vancomycin Resistance in Enterococcus faecium Clinical Isolates Responsible for Bloodstream Infections in US Hospitals Over Ten Years (2010-2019) and Activity of Oritavancin. Lead author: CG Carvalhaes presented at IDWeek 2020, October 21-22, Virtual Conference
Poster #1629

Activity of Manogepix (APX001A) against 2,669 Fungal Isolates from the SENTRY Surveillance Program (2018–2019) Stratified by Infection Type. Lead author, MD Huband, presented at IDWeek 2020, October 21-22, Virtual Conference.

Poster #1260

Susceptibility trends of ceftolozane/tazobactam and comparators when tested against European Gram-negative bacterial surveillance isolates collected during 2012-18. by Sader HS, Carvalhaes CG, Duncan LR, Flamm RK and Shortridge D. published in J. Antimicrob. Chemother. 2020; 75 (10): 2907-2913

Antimicrobial activity of ceftazidime-avibactam, ceftolozane-tazobactam and comparators tested against Pseudomonas aeruginosa and Klebsiella pneumoniae Isolates from United States medical centers in 2016-2018. by Sader HS, Carvalhaes CG, Streit JM, Doyle TB and Castanheira M. published in Microb. Drug Resist. 2021; 27 (3): 342-349

Ceftazidime-avibactam activity against a challenge set of carbapenem-resistant Enterobacterales: Ompk36 L3 alterations and beta-lactamases with ceftazidime hydrolytic activity lead to elevated MIC values. by Castanheira M, Doyle TB, Hubler C, Sader HS and Mendes RE. published in Int. J. Antimicrob. Agents. 2020; 56 (1): 106011, 2020

In vitro activity of KHP-3757 (a novel LpxC inhibitor) and comparator agents against recent and molecularly characterized Pseudomonas aeruginosa isolates from a global surveillance program (2017-2018). by Huband MD, Lindley JM, Mendes RE, Fedler KA, Benn VJ, Zhang J, Zhong G, Li L, Zhang M, Tan X and Flamm RK. published in Diag. Microbio. Infect. Dis. 2020; 98 (4): 115191

Update on the in vitro activity of dalbavancin against indicated species (Staphylococcus aureus, Enterococcus faecalis, beta-hemolytic streptococci, and Streptococcus anginosus group) collected from United States hospitals in 2017-2019. by Sader HS, Streit JM and Mendes RE. published in Diagn. Microbiol. Infect. Dis. 2020; 99 (1): 115195